Apolipoprotein E (ApoE) is known for its role in lipid trafficking and the ɛ4 allele is a risk factor for late onset Alzheimer’s disease (AD). Recently, aberrant ceramide and fatty acid (FA) levels have been implicated in AD.
Objective:
To determine the specific effects of human ApoE4 (hE4) on cerebral ceramide and FA content during chow or a high fat/high cholesterol (HFHC) diet.
Methods:
Cerebral ceramide and FA profiles were determined by LC-MSMS in 15-month-old female wild-type (WT), ApoE-knockout (E0), and hE4-knockin mice fed chow or a HFHC diet for 3 months. mRNA levels of genes involved in ceramide and FA metabolism were determined by qPCR.
Results:
Similar to E0, hE4 mice displayed lower cerebral total ceramide, Cer16 : 0, and Cer24 : 1 levels than WT mice on both diets. Akin to WT mice, hE4 mice had lower total and saturated FA levels on chow than E0 mice. The HFHC diet significantly increased total and saturated FA levels in hE4 mice. Chow-fed hE4 mice showed lower mRNA levels of ceramide synthase (CerS) 6, acid sphingomyelinase, and of most ceramide and FA transporters than WT and E0 mice. The HFHC diet downregulated the expression of CerSs in hE4 and WT mice, and of ceramide and FA transporters in WT mice, but not in E0 mice.
Conclusion:
hE4 reduced cerebral ceramide levels to levels observed in E0 mice independent of diet. The HFHC diet increased cerebral FA levels in hE4 mice. This was associated with alterations in the expression of ceramide and FA transporters specifically in hE4 mice.
CorderEH, SaundersAM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesAD, HainesJL, Pericak-VanceMA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
2.
StrittmatterWJ, SaundersAM, SchmechelD, Pericak-VanceM, EnghildJ, SalvesenGS, RosesAD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A90, 1977–1981.
3.
HoltzmanDM, HerzJ, BuG (2012) Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med2, a006312.
4.
WilliamsDL, DawsonPA, NewmanTC, RudelLL (1985) Synthesis of apolipoprotein E by peripheral tissues. Potential functions in reverse cholesterol transport and cellular cholesterol metabolism. Ann N Y Acad Sci454, 222–229.
5.
MahleyRW (1988) Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science240, 622–630.
6.
PitasRE, BoylesJK, LeeSH, FossD, MahleyRW (1987) Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta917, 148–161.
7.
AbildayevaK, JansenPJ, Hirsch-ReinshagenV, BloksVW, BakkerAH, RamaekersFC, de VenteJ, GroenAK, WellingtonCL, KuipersF, MulderM (2006) 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem281, 12799–12808.
8.
BjorkhemI, MeaneyS (2004) Brain cholesterol: Long secret life behind a barrier. Arterioscler Thromb Vasc Biol24, 806–815.
9.
StrazielleN, Ghersi-EgeaJF (2013) Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm10, 1473–1491.
10.
DietschyJM, TurleySD (2001) Cholesterol metabolism in the brain. Curr Opin Lipidol12, 105–112.
11.
HaugheyNJ, BandaruVV, BaeM, MattsonMP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim Biophys Acta1801, 878–886.
12.
LiuY, PetersonDA, SchubertD (1998) Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci U S A95, 13266–13271.
13.
MencarelliC, BodeGH, LosenM, KulhariaM, MolenaarPC, VeerhuisR, SteinbuschHW, De BaetsMH, NicolaesGA, Martinez-MartinezP (2012) Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques. J Biol Chem287, 14897–14911.
14.
LimWL, MartinsIJ, MartinsRN (2014) The involvement of lipids in Alzheimer’s disease. J Genet Genomics41, 261–274.
15.
MartinsIJ, HoneE, FosterJK, Sunram-LeaSI, GnjecA, FullerSJ, NolanD, GandySE, MartinsRN (2006) Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry11, 721–736.
16.
MulderM, RavidR, SwaabDF, de KloetER, HaasdijkED, JulkJ, van der BoomJJ, HavekesLM (1998) Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord12, 198–203.
17.
MulderM, BloklandA, van den BergDJ, SchultenH, BakkerAH, TerwelD, HonigW, de KloetER, HavekesLM, SteinbuschHW, de LangeEC (2001) Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. Lab Invest81, 953–960.
18.
AstaritaG, AhmedF, PiomelliD (2009) Lipidomic analysis of biological samples by liquid chromatography coupled to mass spectrometry. Methods Mol Biol579, 201–219.
19.
ZhuL, ZhongM, ElderGA, SanoM, HoltzmanDM, GandyS, CardozoC, HaroutunianV, RobakisNK, CaiD (2015) Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer’s disease pathogenesis. Proc Natl Acad Sci U S A112, 11965–11970.
20.
IgbavboaU, HamiltonJ, KimHY, SunGY, WoodWG (2002) A new role for apolipoprotein E: Modulating transport of polyunsaturated phospholipid molecular species in synaptic plasma membranes. J Neurochem80, 255–261.
21.
BandaruVV, TroncosoJ, WheelerD, PletnikovaO, WangJ, ConantK, HaugheyNJ (2009) ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer’s but not normal brain. Neurobiol Aging30, 591–599.
22.
MielkeMM, HaugheyNJ, BandaruVV, ZetterbergH, BlennowK, AndreassonU, JohnsonSC, GleasonCE, BlazelHM, PuglielliL, SagerMA, AsthanaS, CarlssonCM (2014) Cerebrospinal fluid sphingolipids, beta-amyloid, and tau in adults at risk for Alzheimer’s disease. Neurobiol Aging35, 2486–2494.
23.
HanX (2010) Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer’s disease. Biochim Biophys Acta1801, 774–783.
24.
MencarelliC, Martinez-MartinezP (2013) Ceramide function in the brain: When a slight tilt is enough, Cell Mol Life Sci70, 181–203.
25.
MielkeMM, HaugheyNJ (2012) Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer’s disease?Clin Lipidol7, 525–536.
26.
TahaTA, MullenTD, ObeidLM (2006) A house divided: Ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death. Biochim Biophys Acta1758, 2027–2036.
27.
MathiasS, PenaLA, KolesnickRN (1998) Signal transduction of stress via ceramide. Biochem J335(Pt 3), 465–480.
28.
ArigaT, JarvisWD, YuRK (1998) Role of sphingolipid-mediated cell death in neurodegenerative diseases. J Lipid Res39, 1–16.
29.
LimWL, LamSM, ShuiG, MondalA, OngD, DuanX, CreeganR, MartinsIJ, SharmanMJ, TaddeiK, VerdileG, WenkMR, MartinsRN (2013) Effects of a high-fat, high-cholesterol diet on brain lipid profiles in apolipoprotein E epsilon3 and epsilon4 knock-in mice. Neurobiol Aging34, 2217–2224.
30.
SharmanMJ, ShuiG, FernandisAZ, LimWL, BergerT, HoneE, TaddeiK, MartinsIJ, GhisoJ, BuxbaumJD, GandyS, WenkMR, MartinsRN (2010) Profiling brain and plasma lipids in human APOE epsilon2, epsilon3, and epsilon4 knock-in mice using electrospray ionization mass spectrometry. J Alzheimers Dis20, 105–111.
31.
KuoYM, EmmerlingMR, BisgaierCL, EssenburgAD, LampertHC, DrummD, RoherAE (1998) Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun252, 711–715.
32.
MerchedA, XiaY, VisvikisS, SerotJM, SiestG (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol Aging21, 27–30.
33.
RoherAE, KuoYM, KokjohnKM, EmmerlingMR, GraconS (1999) Amyloid and lipids in the pathology of Alzheimer disease. Amyloid6, 136–145.
LedreuxA, WangX, SchultzbergM, GranholmAC, FreemanLR (2016) Detrimental effects of a high fat/high cholesterol diet on memory and hippocampal markers in aged rats. Behav Brain Res312, 294–304.
37.
RaichurS, WangST, ChanPW, LiY, ChingJ, ChaurasiaB, DograS, OhmanMK, TakedaK, SugiiS, Pewzner-JungY, FutermanAH, SummersSA (2014) CerS2 haploinsufficiency inhibits beta-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab20, 687–695.
38.
YuyamaK, MitsutakeS, IgarashiY (2014) Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer’s disease. Biochim Biophys Acta1841, 793–798.
39.
PatilS, MelroseJ, ChanC (2007) Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci26, 2131–2141.
40.
BurckhardtM, HerkeM, WustmannT, WatzkeS, LangerG, FinkA (2016) Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev4, CD009002.
41.
Chouinard-WatkinsR, PlourdeM (2014) Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: Is it contributing to higher risk of cognitive decline and coronary heart disease?Nutrients6, 4452–4471.
42.
HattersDM, Peters-LibeuCA, WeisgraberKH (2005) Engineering conformational destabilization into mouse apolipoprotein E. A model for a unique property of human apolipoprotein E4. J Biol Chem280, 26477–26482.
43.
HuangY (2011) Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer’s disease: Lessons from ApoE mouse models. Biochem Soc Trans39, 924–932.
44.
JanssenCI, JansenD, MutsaersMP, DederenPJ, GeenenB, MulderMT, KiliaanAJ (2016) The effect of a high-fat diet on brain plasticity, inflammation and cognition in female ApoE4-knockin and ApoE-knockout mice. PLoS One11, e0155307.
45.
SullivanPM, MezdourH, ArataniY, KnouffC, NajibJ, ReddickRL, QuarfordtSH, MaedaN (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem272, 17972–17980.
46.
VinaJ, LloretA (2010) Why women have more Alzheimer’s disease than men: Gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimers Dis20(Suppl 2), S527–S533.
47.
VandesompeleJ, De PreterK, PattynF, PoppeB, Van RoyN, De PaepeA, SpelemanF (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol3, RESEARCH0034.
48.
DixonWJ (1959) Analysis of extreme values. Ann Math Stat21, 488–506.
49.
DixonWJ (1959) Ratios involving extreme values. Ann Math Stat22, 68–78.
50.
HanadaK (2003) Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta1632, 16–30.
51.
KolterT, SandhoffK (2005) Principles of lysosomal membrane digestion: Stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids. Annu Rev Cell Dev Biol21, 81–103.
52.
GattS (1963) Enzymic hydrolysis and synthesis of ceramides. J Biol Chem238, 3131–3133.
53.
SutrinaSL, ChenWW (1982) Metabolism of ceramide-containing endocytotic vesicles in human diploid fibroblasts. J Biol Chem257, 3039–3044.
54.
HanadaK, KumagaiK, YasudaS, MiuraY, KawanoM, FukasawaM, NishijimaM (2003) Molecular machinery for non-vesicular trafficking of ceramide. Nature426, 803–809.
55.
MencarelliC, LosenM, HammelsC, De VryJ, HesselinkMK, SteinbuschHW, De BaetsMH, Martinez-MartinezP (2010) The ceramide transporter and the Goodpasture antigen binding protein: Onerotein–one function?J Neurochem113, 1369–1386.
56.
HeX, HuangY, LiB, GongCX, SchuchmanEH (2010) Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol Aging31, 398–408.
57.
HanX, HoltzmanDM, McKeelDWjr, KelleyJ, MorrisJC (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: Potential role in disease pathogenesis. J Neurochem82, 809–818.
58.
KatselP, LiC, HaroutunianV (2007) Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: A shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease?Neurochem Res32, 845–856.
59.
FilippovV, SongMA, ZhangK, VintersHV, TungS, KirschWM, YangJ, Duerksen-HughesPJ (2012) Increased ceramide in brains with Alzheimer’s and other neurodegenerative diseases. J Alzheimers Dis29, 537–547.
60.
CutlerRG, KellyJ, StorieK, PedersenWA, TammaraA, HatanpaaK, TroncosoJC, MattsonMP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci U S A101, 2070–2075.
61.
HejaziL, WongJW, ChengD, ProschogoN, EbrahimiD, GarnerB, DonAS (2011) Mass and relative elution time profiling: Two-dimensional analysis of sphingolipids in Alzheimer’s disease brains. Biochem J438, 165–175.
62.
van Echten-DeckertG, WalterJ (2012) Sphingolipids: Critical players in Alzheimer’s disease. Prog Lipid Res51, 378–393.
63.
BarrierL, IngrandS, FauconneauB, PageG (2010) Gender-dependent accumulation of ceramides in the cerebral cortex of the APP(SL)/PS1Ki mouse model of Alzheimer’s disease. Neurobiol Aging31, 1843–1853.
64.
HartmannD, WegnerMS, WangerRA, FerreirosN, SchreiberY, Lucks.J, SchiffmannS, GeisslingerG, GroschS (2013) The equilibrium between long and very long chain ceramides is important for the fate of the cell and can be influenced by co-expression of CerS. Int J Biochem Cell Biol45, 1195–1203.
HannunYA, ObeidLM (2008) Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat Rev Mol Cell Biol9, 139–150.
68.
FyrstH, SabaJD (2010) An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat Chem Biol6, 489–497.
69.
HannunYA, ObeidLM (2011) Many ceramides. J Biol Chem286, 27855–27862.
70.
PanY, ScanlonMJ, OwadaY, YamamotoY, PorterCJ, NicolazzoJA (2015) Fatty acid-binding protein 5 facilitates the blood-brain barrier transport of docosahexaenoic acid. Mol Pharm12, 4375–4385.
71.
MatsumataM, InadaH, OsumiN (2016) Fatty acid binding proteins and the nervous system: Their impact on mental conditions. Neurosci Res102, 47–55.
72.
YuS, LeviL, CasadesusG, KunosG, NoyN (2014) Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) in the brain. J Biol Chem289, 12748–12758.
73.
KhanW, AguilarC, KiddleSJ, DoyleO, ThambisettyM, MuehlboeckS, SattleckerM, NewhouseS, LovestoneS, DobsonR, GiampietroV, WestmanE, SimmonsA, Alzheimer’s Disease Neuroimaging Initative (2015) A subset of cerebrospinal fluid proteins from a multi-analyte panel associated with brain atrophy, disease classification and prediction in Alzheimer’s disease. PLoS One10, e0134368.
74.
MoulleVS, CansellC, LuquetS, Cruciani-GuglielmacciC (2012) The multiple roles of fatty acid handling proteins in brain. Front Physiol3, 385.
75.
MitchellRW, OnNH, Del BigioMR, MillerDW, HatchGM (2011) Fatty acid transport protein expression in human brain and potential role in fatty acid transport across human brain microvessel endothelial cells. J Neurochem117, 735–746.
76.
GrimmMO, ZimmerVC, LehmannJ, GrimmHS, HartmannT (2013) The impact of cholesterol, DHA, and sphingolipids on Alzheimer’s disease. Biomed Res Int2013, 814390.
77.
CasaliBT, CoronaAW, MarianiMM, KarloJC, GhosalK, LandrethGE (2015) Omega-3 fatty acids augment the actions of nuclear receptor agonists in a mouse model of Alzheimer’s disease. J Neurosci35, 9173–9181.
78.
VandalM, AlataW, TremblayC, Rioux-PerreaultC, SalemNjr, CalonF, PlourdeM (2014) Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem129, 516–526.
79.
TeunissenCE, VeerhuisR, De VenteJ, VerheyFR, VreelingF, van BoxtelMP, GlatzJF, PelsersMA (2011) Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. Eur J Neurol18, 865–871.
80.
Kariv-InbalZ, YacobsonS, BerkeczR, PeterM, JanakyT, LutjohannD, BroersenLM, HartmannT, MichaelsonDM (2012) The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis28, 667–683.
81.
HussainG, SchmittF, LoefflerJP, Gonzalez de AguilarJL (2013) Fatting the brain: A brief of recent research. Front Cell Neurosci7, 144.
GranholmAC, Bimonte-NelsonHA, MooreAB, NelsonME, FreemanLR, SambamurtiK (2008) Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat. J Alzheimers Dis14, 133–145.
84.
PatilS, ChanC (2005) Palmitic and stearic fatty acids induce Alzheimer-like hyperphosphorylation of tau in primary rat cortical neurons. Neurosci Lett384, 288–293.
85.
PatilS, ShengL, MasserangA, ChanC (2006) Palmitic acid-treated astrocytes induce BACE1 upregulation and accumulation of C-terminal fragment of APP in primary cortical neurons. Neurosci Lett406, 55–59.
